Oxford BioTherapeutics
- Health
Boehringer Ingelheim and Oxford BioTherapeutics Expand Collaboration to Discover Novel Selective Tumor Targets as First Bispecific Antibody Advanced into the Clinic
Oxford, England & Ingelheim, Germany: The collaboration for the discovery of novel selective tumor targets for Boehringer Ingelheim’s unique T-cell…
Read More »